Back to today’s briefing

Story perspectives

Study: Lecanemab's Side Effects Manageable, No Fatalities Reported

5/14/2025

24 4

Summary

Story summary

A recent study published in JAMA Neurology reveals that the side effects of lecanemab, an FDA-approved Alzheimer's drug, are manageable. Out of 234 patients, 22% showed amyloid-related imaging abnormalities, with mild dementia patients at greater risk. Encouragingly, no fatalities were reported, but delaying treatment could heighten the risk of side effects.

1 of 1

Story summary

A recent study published in JAMA Neurology reveals that the side effects of lecanemab, an FDA-approved Alzheimer's drug, are manageable. Out of 234 patients, 22% showed amyloid-related imaging abnormalities, with mild dementia patients at greater risk. Encouragingly, no fatalities were reported, but delaying treatment could heighten the risk of side effects.